MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Quality of life assessment in patients with Parkinson’s disease

    S. Frikha, O. Ben Othmen, M. Ben Mahmoud, S. Fray, H. Jamoussi, M. Fredj, N. Ben Ali (Tunis, Tunisia)

    Objective: The objective of the study was to assess the quality of life in patients with Parkinson's disease (PD) and to establish statistical correlations with…
  • 2024 International Congress

    Patient and Caregiver Experiences with Huntington Disease: Emotions, Challenges, and Unmet Needs in the Patient Journey

    A. Peyser Levin, E. Kinjo, R. Ribalov, N. Chaijale, A. Yaari (Tel Aviv, Israel)

    Objective: To describe patients' emotional journey from symptom onset and diagnosis to current state and to identify challenges and unmet needs in Huntington disease (HD).…
  • 2024 International Congress

    Ecopipam does not adversely affect Metabolic Parameters in Pediatric Subjects with Tourette Syndrome: Results from a Phase 2b with 12-month Open Label Extension Study

    D. Gilbert, S. Atkinson, G. Karkanias, F. Munschauer, S. Wanaski, T. Cunniff (Cincinnati, USA)

    Objective: Determine if ecopipam is associated with the emergence of clinical features suggestive of metabolic syndrome in pediatric subjects with Tourette Syndrome (TS) Background: Dopamine-2…
  • 2024 International Congress

    Long-term evaluation of advanced Parkinson’s disease burden and clinical outcomes: results from the PROSPECT observational study

    A. Espay, H. Watanabe, A. Lehn, F. Ory-Magne, T. Mestre, D. Safarpour, L. Bergmann, P. Kukreja, K. Onuk, P. Alonso (Cincinnati, USA)

    Objective: Evaluate long-term clinical outcomes and disease burden in people with advanced Parkinson's disease (PwP) with motor fluctuations not optimized by their current medications. Background:…
  • 2024 International Congress

    Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612

    W. Poewe, A. Ellenbogen, N. Lopes, R. Pahwa (Innsbruck, Austria)

    Objective: To characterize infusion site reactions (ISRs) reported as adverse events (AEs) in clinical studies of ND0612. Background: ND0612 is an investigational, subcutaneous infusion of…
  • 2024 International Congress

    Effect of Opicapone and Levodopa on the Different Daily OFF Patterns in Patients with Parkinson’s Disease and Early Motor Fluctuations: Findings from the Korean ADOPTION Study

    J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

    Objective: To evaluate the effect of opicapone (OPC) 50 mg versus an additional 100 mg levodopa (L-DOPA) dose on the different daily OFF patterns in…
  • 2024 International Congress

    Assessing a Video Based Approach at Measuring Parkinson’s Disease Severity – A Validation Study

    BP. Bridges (St. John's, Canada)

    Objective: To validate the Parkinson’s remote interactive monitoring system’s assessment of Parkinson’s disease compared to a clinical assessment completed by a movement disorder specialist. Background:…
  • 2024 International Congress

    Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease

    E. Brown, A. Siderowf, T. Simuni, T. Sherer, M. Brumm, C. Caspell-Garcia, R. Kurth, C. Gochanour, M. Marshall, M. Korell, C. Stanley, L. Concha, C. Soto, K. Marek, C. Tanner (San Francisco, USA)

    Objective: To evaluate the proportion of people with dopaminergic deficit and positive alpha-synuclein seed amplification assay (aSyn SAA) among a remotely identified group of hyposmic…
  • 2024 International Congress

    Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)

    G. Cordeiro, I. Peixoto, H. Gama, L. Magalhães, J. Moreira, J-F. Rocha, J. Holenz (Trofa, Portugal)

    Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…
  • 2024 International Congress

    Remotely-deployed gamification intervention to increase physical activity in Parkinson’s Disease

    K. Waddell, M. Smith, S. Wood, R. Greysen, J. Morley (Philadelphia, USA)

    Objective: To describe a remote, behavioral intervention designed to increase daily steps in Veterans with PD and report interim results from an ongoing clinical trial…
  • « Previous Page
  • 1
  • …
  • 93
  • 94
  • 95
  • 96
  • 97
  • …
  • 181
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley